E. David Pampe, M.D.

CV Addendum – April 9, 2020

A Randomized, Observer-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a XXXX Influenza Vaccine in Adults 18-64 Years of Age

Double-Blind, Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety, Tolerability, Efficacy, and Immunogenicity of a 2-Dose and 3-Dose Regimen of XXXX, Human Cytomegalovirus (HCMV) Vaccine in Healthy Sero-negative Adolescent and Adult Women

Phase 3: Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of XXXX (XXXX) Orally Disntegrating Tablet (ODT) for the Acute Treatment of Migraine

A Randomized, Observer-blind, Active Comparator-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a XXXX Influenza Vaccine in Adults 65 Years of Age and Older

A Phase II, randomized, double-blind, placebo-controlled study of the safety and efficacy of XXXX in patients with moderate to severe active systemic lupus erythematosus

Efficacy and safety of XXXX once-weekly versus placebo as add-on to SGLT-2i in subjects with type 2 diabetes mellitus

A Phase 3, Multicenter, Randomized, Double-Blind, Placebocontrolled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability Of Multiple Dosing Regimens of Oral XXXX for the Prevention of Migraine in Patients with Episodic Migraine

A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral XXXX-XXXX in Episodic Migraine Prevention

A Randomized, Observer-Blind, Placebo-Controlled Phase 3 Trial to Investigate the Immunogenicity and Safety of a XXXX Dengue Vaccine Candidate and a Yellow Fever XXXX Vaccine Administered Concomitantly and Sequentially in Healthy Subjects Aged 18 to 60 years in Non-Endemic Country(ies)

A Randomized, Double-Blind Study to Compare the Efficacy, Safety and Long-Term Safety of Topical Administration of XXXX-XXXX for 1 Year in the Treatment of Moderate-to-Severe Acne Vulgaris

COAST-1: Clinical Knee Osteoarthritis Symptom Treatment 1 Study A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of XXXX (XXXX XXXX XXXX) Administered Orally to Subjects with Knee Osteoarthritis Associated with Bone Marrow Lesions.

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral XXXX in the Acute Treatment of Migraine

A Randomized, Double-Blind, Vehicle and Active-Controlled Study to Assess the Safety and Local Tolerability of XXXX compared to Reference Listed Drug in the Topical Treatment of Acne Vulgaris for 12 Weeks

An Open-label Long term Safety Study of XXXX (200 mg and 100 mg) in the Acute Treatment of Migraine

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy, Tolerability and Safety Study of XXXX-XX in Episodic Migraine With or Without Aura

A Phase 3, Randomized, Double-Blind Study Comparing XXXX to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(ies)

A Phase Ii, Open-Label Extension Study Of Patients Previously Enrolled In Study XXXX To Evaluate The Long-Term Safety And Efficacy Of XXXX In Patients With Moderate To Severe Active Systemic Lupus Erythematosus

A Study of Three Doses of XXXX (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study (XXXX)

A Phase 3, Placebo-Controlled, Randomized, Observer-Blinded, Study to Evaluate the Efficacy, Safety and Tolerability of a Clostridium Difficile Vaccine in Adults Aged 50 Years and Older

A Randomized, Double-Blind, Placebo-Controlled, Single Dose, 52-Week Study To Evaluate The Safety And Efficacy Of Intra-Articular Injections Of XXXX In Subjects With Chronic, Moderate To Severe Osteoarthritis Knee Pain

A Phase 2, 24-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of XXXX for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

A Randomized, Non-Controlled, Double-Blind Phase 3 Study to Investigate the Long-Term Safety of one or two XXXX doses in Women Suffering From Vasomotor Symptoms (Hot Flashes) Associated with Menopause

A Randomized, Double-Blind, Placebo-Controlled Parallel Study with an Open-Label Extension to Assess the Impact of Testosterone Solution on Total Testosterone, Sex Drive and Energy in Hypogonadal Men

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of XXXX in Women Suffering From Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated with Menopause

A 52-Week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing XXXX with Placebo and with Tofacitinib in Combination with Conventional Synthetic DMARDs, in Participants with Moderately to Severely Active Rheumatoid Arthritis.

Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of XXXX in Migraine Prevention

A Phase 2 Study to Investigate the Safety and Efficacy of XXXX and XXXX Given Alone or in Combination (XXXX Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus

A Phase 3, Randomized, Double-blind, Parallel-group Trial to Evaluate the Lot Consistency, Immunogenicity, and Safety of XXXX for Postexposure Prophylaxis of Anthrax in Healthy Adults

A Phase 3, 56-Week, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study Utilizing Patient Reported and Radiographic Outcomes to Evaluate the Efficacy and Safety of a Single Injection of XXXX Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects.

A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus Vaccine XXXX in Healthy Adults

A Randomized, Placebo-Controlled, Double-Blinded, Parallel, Phase 2a Study to Evaluate the Safety and Efficacy of XXXX in Patients with Primary Hypertension

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study to Evaluate the Safety, Tolerability, and Efficacy of XXXX in the Treatment of Subjects with Overactive Bladder (OAB).

An Open-Label Multi-Center Sub-Study to Evaluate the Efficacy, Safety and Tolerability of XXXX in Patients With Type 2 Diabetes With High Baseline HbA1c

A Randomized, Multicenter Study to Evaluate Cardiovascular Outcomes with XXXX in Patients Treated with Standard of Care for Type 2 Diabetes

A Study to Assess Repeat Treatment Efficacy and Safety of XXXX 550 mg TID in Subjects with Irritable Bowel Syndrome with Diarrhea (IBS-D)

A Randomized, 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of XXXX in Patients with Chronic Idiopathic Constipation

A Phase III, Stratified, Randomized, Double-Blind, Multicenter, Non-Inferiority Study to Evaluate the Safety and Immunogenicity of a Cell-based Quadrivalent Subunit Influenza Virus Vaccine and Cell- based Trivalent Subunit Influenza Virus Vaccines in Adults.

Efficacy, Immunogenicity, and Safety Study Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection

Phase 1 Study of the Safety and Immunogenicity of a XXXX: A Quadrivalent Influenza Vaccine in Healthy Adults Age 18-40 Years

Pharmacokinetic Evaluations of XXXX Following Subcutaneous Administration by Prefilled Syringe or Auto-Injector in Patients with Systemic Lupus Erythematosus

A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of a 12- or 8-Week Treatment Regimen of Simeprevir in Combination with Sofosbuvir in Treatment-Naïve and -Experienced Subjects with Chronic Genotype 1 Hepatitis C

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous XXXX with Placebo for the Preventive Treatment of High Frequency Episodic Migraine

A Double-Blind, Randomised, Placebo-Controlled, Four Parallel Arm, Dose-Finding Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Single Intra-Articular Injections of XXXX in Patients with Symptomatic Osteoarthritis of the Knee

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of XXXX, a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite Anti-TNFa Therapy

A Randomized, Double-Blind, Factorial Study to Compare the Safety and Efficacy of Varying Combinations of XXXX and XXXX in Subjects with Genital HSV-2 Infection

A Phase 2, Randomized, Active-Controlled, Observer-Blinded Trial to Assess the Safety, Tolerability and Immunogenicity of XXXX, Tdap Vaccine and Bivalent XXXX Vaccine When Administered Concomitantly in Healthy Subjects Aged > = to 10 Years to Less Than 1

A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of XXXX in Subjects with Osteoarthritis of the Knee

A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-dose Study Comparing the Efficacy and Safety of Subcutaneous XXXX with Placebo for the Preventive Treatment of Chronic Migraine

A Phase 3b, Multicenter, Randomized, Placebo-Controlled, Double Blind, Double-Dummy, Study of the Efficacy and Safety of XXXX, XXXX, and Placebo in Subjects with Moderate to Severe Plaque Psoriasis.

A Global Phase 3 Safety Study of 120 Mcg XXXX Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of a 12- or 8-Week Treatment Regimen of XXXX in Combination with XXXX in Treatment-Naïve and -Experienced Subjects with Chronic Genotype 1 Hepatitis C Virus Infection With Cirrhosis.

A Multicenter, Parallel-group Study of Long-term Safety and Efficacy of XXXX for Rheumatoid Arthritis in Subjects Completing Treatment in Studies XXXX and XXXX.

A Randomized, Double-Blind, Placebo-Controlled Multicenterstudy Of XXXX To Evaluate The Safety, Tolerability And Efficacy Up To 2 Years In Patients With Active Nonradiographic Axial Spondyloarthritis

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Analgesic Efficacy and Safety of a Dose Titration Regimen for the Subcutaneous Administration of XXXX in Subjects with Osteoarthritis of the Hip or Knee

A Phase 3 Randomized, Double-Blind, Active-Controlled, Multicenter Study of the Long-Term Safety and Efficacy of Subcutaneous Administration of XXXX in Subjects with Osteoarthritis of the Hip or Knee

Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of XXXX as Adjunctive Therapy in Subjects with Signs and Symptoms of Osteoarthritis of the Hip or Knee

A Randomized, Double-Blind Study to Evaluate a New Formulation of XXXX in Subjects with Genital HSV-2 Infection

A Phase 2, Multicenter, Randomized, Double-Blind, PlaceboControlled Study Evaluating the Safety, Tolerability, and Efficacy of XXXX Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects

XXXX, Multi-center, Double-Blind, Double-Dummy, Randomized, Placebo- and Active-Reference, Parallel Group, Phase 2 Dose-Finding Study with XXXX in Subjects with Essential Hypertension (grade 1 and 2).

A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of XXXX Administered Intravenously in Patients with Frequent Episodic Migraines.

A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of XXXX Versus Three-Day XXXX for the Treatment of Group A β-Hemolytic Streptococcal Pharyngitis/Tonsillitis in Adolescents and Adults